It may be useful in patients who have achieved their goal weight and are using lower doses to maintain their weight. However, early data and clinical experience suggest that it is an effective strategy, Orandi commented
Comparator Selection : Many trials use placebo comparisons rather than active comparators, limiting understanding of relative effectiveness compared to existing obesity treatments
Scand J Gastroenterol 2004: 36
Klinic specializes in these alternatives
It should also be noted that, from a methodological perspective, the model used (Cox with stratification by cardiovascular risk class of the trials, i.e., SURPASS-4: high risk, and all others: low risk) requires various assumptions, including the homogeneity of the relative effect of tirzepatide treatment on MACE regardless of the baseline cardiovascular risk level of the patients
What nutrition